Quick Answer
BIO-TECHNE Corp reported Cash and Equivalents of $162.19 million for fiscal year 2025.
BIO-TECHNE Corp Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $162.19M | +6.8% |
| 2024 | $151.79M | -15.9% |
| 2023 | $180.57M | +4.6% |
| 2022 | $172.57M | -13.3% |
| 2021 | $199.09M | +35.8% |
| 2020 | $146.62M | +45.3% |
| 2019 | $100.89M | -17.3% |
| 2018 | $121.99M | +33.2% |
| 2017 | $91.61M | +42.6% |
| 2016 | $64.24M | +17.8% |
| 2015 | $54.53M | -82.9% |
| 2014 | $318.57M | +94.5% |
| 2013 | $163.79M | +40.4% |
| 2012 | $116.67M | +50.3% |
| 2011 | $77.61M | -17.6% |
| 2010 | $94.14M | -41.5% |
| 2009 | $160.94M | -3.6% |
| 2008 | $166.99M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | $172.88M | -2.6% | +19.3% |
| September 30, 2025 | $144.96M | -22.7% | -10.6% |
| June 30, 2025 | $162.19M | +6.8% | +15.3% |
| March 31, 2025 | $140.67M | +0.5% | -20.8% |
| December 31, 2024 | $177.55M | +36.4% | -5.3% |
| September 30, 2024 | $187.54M | +26.2% | +23.6% |
| June 30, 2024 | $151.79M | -15.9% | +8.5% |
| March 31, 2024 | $139.91M | +9.9% | +7.5% |
- BIO-TECHNE Corp showed an increase of +6.8% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2008–2025 period, BIO-TECHNE Corp’s cash and equivalents has declined by 2.9% (from $166.99 million to $162.19 million).
- The most recent figure is from BIO-TECHNE Corp’s fiscal year 2025 report (Form 10-K), filed with the SEC on August 22, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: